Atlas Trials

Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC

Clinical trial NCT04157140 · UNKNOWN

Trial details

NCT number
NCT04157140
Sponsor
Jinglong Chen
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2019-11-28
Primary completion
2022-09-01
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.